Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05007106 · ClinicalTrials.gov registry record · Phase 2
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
A Phase 2 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 2
- Development phase
- 613
- Enrollment target
NCT05007106 is a Phase 2 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 613 participants.
The verdict
NCT05007106, a Phase 2 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 613 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. The primary hypothesis is that pembrolizumab/vibostolimab co-formulation is superior to pembrolizumab alone in terms of objective response rate or progression-free survival in participants with cervical cancer.
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Cisplatin
- DRUG 5-Fluorouracil
- DRUG Lenvatinib
- BIOLOGICAL Pembrolizumab/Vibostolimab Co-Formulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 613 participants |
| Start Date | 2021-09-16 |
| Est. Completion | 2025-08-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05007106
The ClinicalTrials.gov registry entry for NCT05007106 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 613 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT05007106 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05007106 about?
NCT05007106 is a clinical study titled "MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)". The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. The primary hypothesis is that pembrolizumab/vibostolim...
What is the current status of trial NCT05007106?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 613 participants. The study started on 2021-09-16. Estimated completion is 2025-08-05.
What interventions are being tested in trial NCT05007106?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Cisplatin (DRUG), 5-Fluorouracil (DRUG), Lenvatinib (DRUG), Pembrolizumab/Vibostolimab Co-Formulation (BIOLOGICAL).
Who is sponsoring clinical trial NCT05007106?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.